Tandem Diabetes Care (TNDM) Cash & Equivalents (2013 - 2026)
Tandem Diabetes Care's (TNDM) quarterly Cash & Equivalents came in at $179.3 million in Q1 2026, up 234.72% YoY from $53.6 million in Q1 2025, and up 97.86% on a QoQ basis from $90.6 million in Q4 2025.
Tandem Diabetes Care (TNDM) Cash & Equivalents (2013 - 2026) Analysis & Trends
Tandem Diabetes Care (TNDM) has 14 years of Cash & Equivalents data on file, last reported at $179.3 million in Q1 2026.
- Quarterly Cash & Equivalents rose 234.72% year-over-year to $179.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $179.3 million (up 234.72% YoY) and the FY2025 annual result came in at $90.6 million, up 30.91% from the prior year.
- Cash & Equivalents rose to $179.3 million in Q1 2026, from $90.6 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $179.3 million in Q1 2026 to a low of $47.7 million in Q2 2024.
- A 5-year average of $94.5 million and a median of $90.6 million in 2025 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2023 — Cash & Equivalents plunged 65.88% — and 2026, when it surged 234.72%.
- Tracing TNDM's Cash & Equivalents over 5 years: stood at $172.5 million in 2022, then sank by 65.88% to $58.9 million in 2023, then advanced by 17.61% to $69.2 million in 2024, then soared by 30.91% to $90.6 million in 2025, then surged by 97.86% to $179.3 million in 2026.
- The last three Cash & Equivalents figures came in at $179.3 million (Q1 2026), $90.6 million (Q4 2025), and $91.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.46 Bn | 193.86 Bn | 7.27 Bn | 5.10 Bn |
| 2 | Stryker | 127.41 Bn | 123.93 Bn | 4.50 Bn | 3.39 Bn |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | 1.95 Bn |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | 539.00 Mn |
| 5 | Edwards Lifesciences | 51.95 Bn | 47.69 Bn | 1.35 Bn | 2.91 Bn |
| 6 | Dexcom | 34.30 Bn | 32.35 Bn | 830.00 Mn | 1.11 Bn |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | 2.11 Bn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.02 Bn | 4.55 Bn | 3.25 Bn |
| 9 | Steris | 23.04 Bn | 22.55 Bn | 684.20 Mn | 482.30 Mn |
| 10 | Tandem Diabetes Care | 1.56 Bn | 1.11 Bn | 144.78 Mn | 62.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 62.82 Mn |
| Mar 31, 2026 | 179.33 Mn |
| Dec 31, 2025 | 90.63 Mn |
| Sep 30, 2025 | 91.95 Mn |
| Jun 30, 2025 | 64.11 Mn |
| Mar 31, 2025 | 53.57 Mn |
| Dec 31, 2024 | 69.23 Mn |
| Sep 30, 2024 | 49.04 Mn |
| Jun 30, 2024 | 47.70 Mn |
| Mar 31, 2024 | 58.98 Mn |
| Dec 31, 2023 | 58.87 Mn |
| Sep 30, 2023 | 79.61 Mn |
| Jun 30, 2023 | 130.75 Mn |
| Mar 31, 2023 | 127.76 Mn |
| Dec 31, 2022 | 172.52 Mn |
| Sep 30, 2022 | 123.79 Mn |
| Jun 30, 2022 | 114.97 Mn |
| Mar 31, 2022 | 93.68 Mn |
| Dec 31, 2021 | 71.18 Mn |
| Sep 30, 2021 | 112.38 Mn |